In this regard, synthetic lethality techniques may provide a broader range of druggable targets to deal with therapy resistance developed toward Top2 inhibitors, which should thus increase the susceptibility of cancer cells to genotoxic therapy. The gene discussed is TOP2A; the disease is cancer.